Meanwhile, the BSE Sensex was up 6.16 points, or 0.02%, to 25,375.06.

On BSE, so far 8,466 shares were traded in the counter, compared with an average volume of 6,063 shares in the past one quarter.

The stock hit a high of Rs 1,144.90 and a low of Rs 1,113.55 so far during the day. The stock hit a 52-week high of Rs 1,285 on 4 March 2014. The stock hit a 52-week low of Rs 634 on 6 August 2013.

The stock had outperformed the market over the past one month till 24 June 2014, rising 3.54% compared with 2.74% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, rising 2.92% as against Sensex's 15.02% rise.

The small-cap company has an equity capital of Rs 5 crore. Face value per share is Rs 2.

Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) shall closely monitor the entire delisting process of Astrazeneca Pharma India and allow the final delisting of its shares only after satisfying themselves that the process has been fair and transparent, the Securities and Exchange Board of India (Sebi) said in an order.

The promoters of Astrazeneca Pharma India shall finally purchase shares from public shareholders in the delisting offer only after seeking approval of the Bombay Stock Exchange and National Stock Exchange, Sebi said.

The regulator also said it came across certain reports that the offer for sale (OFS) of the shares of Astrazeneca Pharma India carried out by its promoter AstraZeneca Pharmaceuticals AB Sweden on 26 May 2013 was a deliberate attempt to subsequently get the shares of the Indian unit delisted at ease.

It was also reported that more than 94% of total shares offered through OFS had been subscribed by six foreign institutional investors including DB International Asia, Suffolk (Mauritius), Morgan Stanley Asia (Singapore) PTE, BNP Paribas Arbitrage, Manfield (Mauritius) and Merrill Lynch Capital Markets Espana S.A. SVB.

AstraZeneca Pharma India on 20 June 2014 announced that its shareholders approved a proposal to delist the company from the bourses.

In March this year, AstraZeneca Pharma India's board had approved the proposal from AstraZeneca Pharmaceuticals AB, Sweden (AZP AB), the promoter of the company, to delist the equity shares of the company from Indian stock exchanges (BSE, NSE and Bangalore Stock Exchange).

AZP AB holds 75% in the Indian unit (as per shareholding pattern as on 31 March 2014).

Astrazeneca Pharma India reported net loss of Rs 2.57 crore in Q4 March 2014 as against net loss of Rs 18.58 crore in Q4 March 2013. Net sales rose 20.35% to Rs 114.15 crore in Q4 March 2014 over Q4 March 2013.

AstraZeneca Pharma India is one of the leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.